Abstract
Objective.: Conservative surgery followed by platinum-based chemotherapy is considered the standard approach for stage I immature ovarian teratoma (IT), except for stage IA G1. Nevertheless the use of chemotherapy in stage IA G2-3 and IB-IC is controversial. The aim of this study was to evaluate the outcome of patients with IT in order to define the role of chemotherapy in stage I disease. Methods.: Twenty-eight patients with stage I IT treated in MITO centers were retrospectively reviewed. Grade, stage, age, surgical and postoperative treatment were analyzed using χ2 test and T test looking for association with recurrence. Results.: Median age was 25.5. Twenty-four patients underwent fertility-sparing surgery. FIGO stages were 19 IA, 2 IB, and 7 IC. Nine patients had grade 1 tumor, 12 grade 2, and 7 grade 3. Nine patients received adjuvant chemotherapy. Overall recurrence rate was 21.4% (2 in chemotherapy group and 4 in the group without treatment). No patients with G1 had recurrence, whereas 25% of G2 and 42.9% of G3 relapsed. Recurrence rate was not significantly different according to stage, grade or adjuvant chemotherapy, whereas it was greater in the group not operated in a MITO center, not staged and of age lower than 20 years, with statistical significance. At recurrence 4 patients presenting with mature teratoma were treated with surgery alone, whereas 2 recurring with IT were treated with surgery plus chemotherapy. After a median follow-up of 59 months all patients are NED. Conclusions.: Our study suggests that chemotherapy may be withheld for primary therapy and utilized only for recurrence.
| Original language | English |
|---|---|
| Pages (from-to) | 48-52 |
| Number of pages | 5 |
| Journal | Gynecologic Oncology |
| Volume | 119 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Oct 2010 |
Fingerprint
Keywords
- Chemotherapy
- Immature teratoma
- Recurrence
- Stage I
- Surveillance
ASJC Scopus subject areas
- Obstetrics and Gynaecology
- Oncology
- Medicine(all)
Cite this
Is adjuvant chemotherapy indicated in stage i pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9). / Mangili, G.; Scarfone, G.; Gadducci, A.; Sigismondi, C.; Ferrandina, G.; Scibilia, G.; Viganò, R.; Tateo, S.; Villa, A.; Lorusso, D.
In: Gynecologic Oncology, Vol. 119, No. 1, 10.2010, p. 48-52.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Is adjuvant chemotherapy indicated in stage i pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9)
AU - Mangili, G.
AU - Scarfone, G.
AU - Gadducci, A.
AU - Sigismondi, C.
AU - Ferrandina, G.
AU - Scibilia, G.
AU - Viganò, R.
AU - Tateo, S.
AU - Villa, A.
AU - Lorusso, D.
PY - 2010/10
Y1 - 2010/10
N2 - Objective.: Conservative surgery followed by platinum-based chemotherapy is considered the standard approach for stage I immature ovarian teratoma (IT), except for stage IA G1. Nevertheless the use of chemotherapy in stage IA G2-3 and IB-IC is controversial. The aim of this study was to evaluate the outcome of patients with IT in order to define the role of chemotherapy in stage I disease. Methods.: Twenty-eight patients with stage I IT treated in MITO centers were retrospectively reviewed. Grade, stage, age, surgical and postoperative treatment were analyzed using χ2 test and T test looking for association with recurrence. Results.: Median age was 25.5. Twenty-four patients underwent fertility-sparing surgery. FIGO stages were 19 IA, 2 IB, and 7 IC. Nine patients had grade 1 tumor, 12 grade 2, and 7 grade 3. Nine patients received adjuvant chemotherapy. Overall recurrence rate was 21.4% (2 in chemotherapy group and 4 in the group without treatment). No patients with G1 had recurrence, whereas 25% of G2 and 42.9% of G3 relapsed. Recurrence rate was not significantly different according to stage, grade or adjuvant chemotherapy, whereas it was greater in the group not operated in a MITO center, not staged and of age lower than 20 years, with statistical significance. At recurrence 4 patients presenting with mature teratoma were treated with surgery alone, whereas 2 recurring with IT were treated with surgery plus chemotherapy. After a median follow-up of 59 months all patients are NED. Conclusions.: Our study suggests that chemotherapy may be withheld for primary therapy and utilized only for recurrence.
AB - Objective.: Conservative surgery followed by platinum-based chemotherapy is considered the standard approach for stage I immature ovarian teratoma (IT), except for stage IA G1. Nevertheless the use of chemotherapy in stage IA G2-3 and IB-IC is controversial. The aim of this study was to evaluate the outcome of patients with IT in order to define the role of chemotherapy in stage I disease. Methods.: Twenty-eight patients with stage I IT treated in MITO centers were retrospectively reviewed. Grade, stage, age, surgical and postoperative treatment were analyzed using χ2 test and T test looking for association with recurrence. Results.: Median age was 25.5. Twenty-four patients underwent fertility-sparing surgery. FIGO stages were 19 IA, 2 IB, and 7 IC. Nine patients had grade 1 tumor, 12 grade 2, and 7 grade 3. Nine patients received adjuvant chemotherapy. Overall recurrence rate was 21.4% (2 in chemotherapy group and 4 in the group without treatment). No patients with G1 had recurrence, whereas 25% of G2 and 42.9% of G3 relapsed. Recurrence rate was not significantly different according to stage, grade or adjuvant chemotherapy, whereas it was greater in the group not operated in a MITO center, not staged and of age lower than 20 years, with statistical significance. At recurrence 4 patients presenting with mature teratoma were treated with surgery alone, whereas 2 recurring with IT were treated with surgery plus chemotherapy. After a median follow-up of 59 months all patients are NED. Conclusions.: Our study suggests that chemotherapy may be withheld for primary therapy and utilized only for recurrence.
KW - Chemotherapy
KW - Immature teratoma
KW - Recurrence
KW - Stage I
KW - Surveillance
UR - http://www.scopus.com/inward/record.url?scp=77956648494&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956648494&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2010.05.035
DO - 10.1016/j.ygyno.2010.05.035
M3 - Article
VL - 119
SP - 48
EP - 52
JO - Gynecologic Oncology
JF - Gynecologic Oncology
SN - 0090-8258
IS - 1
ER -